Skip to main content


Figure 2 | BMC Musculoskeletal Disorders

Figure 2

From: Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): Results from the CanACT study

Figure 2

Response in American College of Rheumatology (ACR) Criteria Following Adalimumab Treatment. Percentages of patients who met the AC R criteria for 20%, 50%, and 70% improvement (ACR20, ACR50, and ACR70, respectively) with adalimumab 40 mg administered subcutaneously every other week with concomitant standard antirheumatic therapy. A.) All randomized patients. B) Subgroup analysis of randomized patients on the basis of experience with biological DMARD (BDMARD) therapy.

Back to article page